Ocular Therapeutix’s Sawhney Discusses Regeneron, FDA

Amar Sawhney, president, CEO, and chairman of Ocular Therapeutix, gives details on his company’s new collaboration with Regeneron to develop a sustained-release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases.



Amar Sawhney

Amar Sawhney

Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014.

View Full Profile